Latest Regulatory News

Tombador Iron Limited reports a quarterly loss amid a strategic acquisition of GoviEx Uranium, signaling a pivot to uranium exploration and a rebrand to Atomic Eagle Limited.

DroneShield Limited has clarified the recent sharp decline in its share price, attributing the market movement to disclosed director share disposals rather than any undisclosed material information.

EBOS Group Limited has updated its Dividend Reinvestment Plan rules, offering shareholders new ways to reinvest dividends into additional shares. The changes, effective immediately, provide greater flexibility and maintain board discretion over share issuance terms.

Hartshead Resources has been granted a two-year extension on Phase C of its UK North Sea Licence P2607, allowing more time to complete its work programme amid regulatory and supply chain delays.

Waratah Minerals has addressed a sharp share price drop and surge in trading volume, attributing the market activity to pending, incomplete exploration results at its Spur Gold-Copper Project.

The ACCC has given informal clearance for the merger between Southern Cross Media Group and Seven West Media, marking a key regulatory milestone. The deal still awaits shareholder and ACMA approvals before completion.

The Australian Competition and Consumer Commission has given the green light to Southern Cross Media’s proposed acquisition of Seven West Media, marking a significant regulatory milestone in the evolving Australian media landscape.

Evergreen Lithium has formalised a binding option to acquire up to 100% of the Mt Monger Gold Project in Western Australia, reinforcing its strategic expansion in the prolific Goldfields region.

The ACCC has decided not to oppose Southern Cross Media’s proposed acquisition of Seven West Media, finding limited competition concerns amid evolving digital media landscapes.

The ACCC has decided not to oppose Southern Cross Media’s proposed acquisition of Seven West Media, citing limited competition concerns amid evolving digital media landscapes.

Anteris Technologies has gained FDA approval to start patient recruitment in the US for its pivotal PARADIGM Trial, following initial European regulatory success. The company advances manufacturing and clinical readiness as it pushes toward key regulatory milestones.

Anteris Technologies Global Corp. reported a $22.2 million loss in Q3 2025 while progressing its DurAVR Transcatheter Heart Valve pivotal trial following key regulatory approvals. The company bolstered its cash position with a $25.2 million private placement post-quarter.